替格瑞洛与氯吡格雷在急性冠脉综合征经皮冠状动脉介入治疗患者中主要不良冠脉事件的关联
该基于人群的队列研究纳入2012年4月1日至2016年3月31日期间因急性冠脉综合征行经皮冠状动脉介入治疗后存活出院的11185例患者,随访至1年。替格瑞洛使用与主要不良冠脉事件风险无显著降低相关(aHR 0.97,95%CI 0.85-1.10),但与大出血(aHR 1.51,95%CI 1.29-1.78)和呼吸困难(aHR 1.98,95%CI 1.47-2.65)风险增加相关。在全队列中,依从性(药物补充依从性≥80%)与较低的主要不良冠脉事件风险相关(aHR 0.79,95%CI 0.69-0.90)。作者结论认为替格瑞洛与氯吡格雷相比未显著减少主要不良冠脉事件,但与大出血和呼吸困难增加相关。
要点
- 在急性冠脉综合征行经皮冠状动脉介入治疗后存活出院的患者中,替格瑞洛与氯吡格雷相比主要不良冠脉事件风险无显著差异(aHR 0.97,95%CI 0.85-1.10)。
- 替格瑞洛与大出血风险增加相关(aHR 1.51,95%CI 1.29-1.78),与呼吸困难风险增加相关(aHR 1.98,95%CI 1.47-2.65)。
- 全队列中,药物补充依从性≥80%与较低的主要不良冠脉事件风险相关(aHR 0.79,95%CI 0.69-0.90)。
- 替格瑞洛使用者中依从者3328例(81.6%),氯吡格雷使用者中依从者5256例(73.9%)(P < .001;χ2 = 86.4)。
- 敏感性分析和亚组分析与主要分析结果一致。
适用人群与场景
- 因急性冠脉综合征行经皮冠状动脉介入治疗后存活出院的患者,数据来自阿尔伯塔省冠心病结局评估项目登记处,出院时间2012年4月1日至2016年3月31日,随访至1年。
- 替格瑞洛使用者通常较氯吡格雷使用者年轻,且心脏和非心脏合并症较少。
诊断标准与关键阈值
- 暴露定义为经皮冠状动脉介入治疗后31天内门诊处方替格瑞洛或氯吡格雷。
- 依从性定义为药物补充依从性值≥80%。
研究设计与关键结果
- 基于人群的队列研究,纳入11185例因急性冠脉综合征行经皮冠状动脉介入治疗后存活出院的患者,随访至365天。
- 主要终点为主要不良冠脉事件(全因死亡、急性冠脉综合征住院、非计划冠脉血运重建或支架内血栓的复合终点):替格瑞洛与氯吡格雷相比aHR 0.97(95%CI 0.85-1.10),无显著差异。
- 次要终点:替格瑞洛与大出血风险增加相关(aHR 1.51,95%CI 1.29-1.78),与呼吸困难风险增加相关(aHR 1.98,95%CI 1.47-2.65)。
- 依从性:替格瑞洛使用者中3328例(81.6%)依从,氯吡格雷使用者中5256例(73.9%)依从(P < .001;χ2 = 86.4)。
- 全队列中,依从性≥80%与<80%相比,主要不良冠脉事件风险aHR 0.79(95%CI 0.69-0.90)。
- 其他次要结局差异无统计学意义;敏感性和亚组分析与主要分析一致。
证据类型、等级与局限
- 证据类型:基于人群的队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在急性冠脉综合征行经皮冠状动脉介入治疗后的患者中,替格瑞洛与氯吡格雷相比主要不良冠脉事件无显著差异,但与大出血和呼吸困难风险增加相关;作者结论认为替格瑞洛与氯吡格雷相比未显著减少主要不良冠脉事件,但与大出血和呼吸困难增加相关。
- 全队列中药物补充依从性≥80%与较低的主要不良冠脉事件风险相关(aHR 0.79,95%CI 0.69-0.90)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
- 另有 1 条提炼内容因数值无法与原文逐一核对而未列出,请以原文为准。
英文原文(摘要)· 点击展开
IMPORTANCE: Guidelines currently recommend ticagrelor over clopidogrel for patients with acute coronary syndrome (ACS) based on randomized clinical trial data in which ticagrelor reduced major adverse coronary events (MACE) vs clopidogrel but increased bleeding and dyspnea.
OBJECTIVE: To compare the risk of MACE with ticagrelor vs clopidogrel in patients with ACS treated with percutaneous coronary intervention (PCI), to compare major bleeding and dyspnea, and to evaluate the association between P2Y12 inhibitor adherence and MACE.
DESIGN, SETTING, AND PARTICIPANTS: Population-based cohort study using data of patients discharged alive after PCI for ACS from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease registry from April 1, 2012, to March 31, 2016, with follow-up to 1 year. Analysis began April 2018.
EXPOSURES: Outpatient prescription for ticagrelor or clopidogrel within 31 days after PCI. Adherence was defined as a medication refill adherence value of 80% or higher.
MAIN OUTCOMES AND MEASURES: Major adverse coronary events, a composite of all-cause death, hospitalization for ACS, unplanned coronary revascularization, or stent thrombosis within 365 days after index PCI. Secondary outcomes included hospitalization for major bleeding and emergency department visit for dyspnea.
RESULTS: Of 11 185 individuals who underwent PCI, the median (interquartile range) age was 61 (54-71) years, and 2760 (24.7%) were women. Ticagrelor users (4076 [36.4%]) were generally younger and had fewer cardiac and noncardiac comorbidities than clopidogrel users. Ticagrelor was not associated with lower risk of MACE (adjusted hazard ratio [aHR], 0.97; 95% CI, 0.85-1.10); however, it was associated with an increased risk of major bleeding (aHR, 1.51; 95% CI, 1.29-1.78) and dyspnea (aHR, 1.98; 95% CI, 1.47-2.65). A total of 3328 ticagrelor users (81.6%) were adherent during the study vs 5256 of clopidogrel users (73.9%) (P < .001; χ2 = 86.4). In the full cohort, adherence was associated with a lower MACE risk (aHR, 0.79; 95% CI, 0.69-0.90 for adherence of ≥80% vs <80%). Differences in other secondary outcomes were not statistically significant. Sensitivity and subgroup analyses were consistent with primary analyses.
CONCLUSIONS AND RELEVANCE: In this population-based cohort study of patients with ACS who underwent PCI, outpatient use of ticagrelor was not associated with a statistically significant reduction in MACE vs clopidogrel; however, it was associated with more major bleeding and dyspnea.
参考来源
- Turgeon RD, Koshman SL, Youngson E, et al. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA Intern Med. 2020. PMID: 31930361. doi:10.1001/jamainternmed.2019.6447
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。